Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 14 of 14 entries
View as:

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT06596772 Org: User:
Start: 10/03/24 End: 01/31/26 Due: 01/31/27

Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04238663 Org: User:
Start: 09/24/19 End: 03/17/20 Due: 03/17/21

A Study Investigating the Safety, Absorption, and Elimination of MB04, a New Compound That May Potentially be Used in the Treatment of Autoimmune Disorders

Phase: N/A Priority: Normal
NCT ID: NCT06392074 Org: User:
Start: 03/07/24 End: 05/31/25 Due: 05/31/26

A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)

Phase: N/A Priority: Normal
NCT ID: NCT06687369 Org: User:
Start: 12/30/24 End: 09/30/27 Due: 09/30/28

A Pharmacokinetic Study Comparing MB02 And US And EU Avastin® In Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT03293654 Org: User:
Start: 12/07/17 End: 05/29/19 Due: 05/29/20

A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT03296163 Org: User:
Start: 02/06/18 End: 02/27/20 Due: 02/27/21

Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients

Phase: N/A Priority: Normal
NCT ID: NCT02069704 Org: User:
Start: 10/29/14 End: 06/30/17 Due: 06/30/18

Exploratory Study to Estimate the Prophylactic Efficacy of Palivizumab in Healthy Adult Participants Inoculated With RSV

Phase: N/A Priority: Normal
NCT ID: NCT04540627 Org: User:
Start: 07/06/20 End: 10/23/20 Due: 10/23/21

A Study to Compare Efficacy, PK, PD, Safety and IMM of MB09 to Prolia® [EU-sourced] in Postmenopausal Osteoporosis.

Phase: N/A Priority: Normal
NCT ID: NCT05338086 Org: User:
Start: 03/16/22 End: 05/22/24 Due: 05/22/25

A PK Study Comparing MB05, EU-sourced Synagis® and US-sourced Synagis® in Healthy Volunteers.

Phase: N/A Priority: Normal
NCT ID: NCT05121246 Org: User:
Start: 06/15/22 End: 03/31/23 Due: 03/31/24

A Study Comparing the Pharmacokinetic Similarity of MB02-SP, MB02-DM and US Licensed-Avastin®.

Phase: N/A Priority: Normal
NCT ID: NCT04408989 Org: User:
Start: 01/11/21 End: 09/02/21 Due: 09/02/22

A Pharmacokinetic Study Comparing MB02 And EU Avastin® In Healthy Male Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT04238650 Org: User:
Start: 08/02/19 End: 12/27/19 Due: 12/27/20

Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT02268045 Org: User:
Start: 05/31/13 End: 07/31/17 Due: 07/31/18

A Study Comparing the Pharmacokinetic Similarity of MB09 and EU/US-Sourced Xgeva

Phase: N/A Priority: Normal
NCT ID: NCT05299073 Org: User:
Start: 03/01/22 End: 03/18/23 Due: 03/18/24